Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EBT (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EBT for 3 consecutive years, with -$32.8 million as the latest value for Q4 2025.

  • Quarterly EBT rose 31.4% to -$32.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$140.1 million through Dec 2025, down 108.3% year-over-year, with the annual reading at -$140.1 million for FY2025, 108.3% down from the prior year.
  • EBT for Q4 2025 was -$32.8 million at Inhibrx Biosciences, up from -$35.3 million in the prior quarter.
  • The five-year high for EBT was $1.9 billion in Q2 2024, with the low at -$92.0 million in Q4 2023.
  • Average EBT over 3 years is $123.3 million, with a median of -$43.9 million recorded in 2024.
  • The sharpest move saw EBT soared 4049.27% in 2024, then crashed 101.54% in 2025.
  • Over 3 years, EBT stood at -$92.0 million in 2023, then surged by 47.96% to -$47.9 million in 2024, then surged by 31.4% to -$32.8 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$32.8 million, -$35.3 million, and -$28.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.